Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Long-Term Debt Repayments (2020 - 2022)

Neurocrine Biosciences (NBIX) has disclosed Long-Term Debt Repayments for 3 consecutive years, with -$100000.0 as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Long-Term Debt Repayments changed N/A year-over-year to -$100000.0, compared with a TTM value of -$100000.0 through Sep 2024, down 100.05%, and an annual FY2024 reading of $308.8 million, changed N/A over the prior year.
  • Long-Term Debt Repayments was -$100000.0 for Q2 2023 at Neurocrine Biosciences, down from $100000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $186.9 million in Q4 2020 and bottomed at -$100000.0 in Q2 2023.
  • Average Long-Term Debt Repayments over 3 years is $62.3 million, with a median of $100000.0 recorded in 2021.